Forest Laboratories (FRX) said Thursday evening that it expects to top Wall Street earnings estimates for the just-closed quarter due to strong drug sales.
The New York-based pharmaceutical firm projects earnings for its fiscal third quarter to exceed by 15% analysts' consensus estimate of 77 cents per share, as polled by Thomson Financial/First Call. In the fiscal third quarter last year, Forest earned 47 cents per share. The company credits strong sales in its antidepressant franchise for the upside surprise. Forest is projecting sales of the antidepressant Celexa should reach $370 million in the quarter. Sales of the antidepressant Lexapro, launched in September, should total about $80 million in the quarter, the company said. Forest will release actual fiscal third-quarter results and guidance for the remainder of its fiscal year on Jan. 16. Forest shares closed Thursday up $1.78 to $100. In after-hours trading following the release of the bullish expectations, the company's stock surged $2 to $102.>To order reprints of this article, click here: ReprintsTheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,890.46 | 1,351.95 | 2,927.23 | 20.47 |
Oil *
118.75
|
|
UP
6.51 |
UP
1.99 |
UP
11.37 |
UP
0.72 |
10 Yr
2.05%
SPDR Gold
168.02
|
|
+0.05%
|
+0.15%
|
+0.39%
|
+3.65%
|
Data delayed 20 minutes |
Connect with TheStreet